Rifaximin Versus No Intervention for the Treatment of IgA Monoclonal Gammopathy of Undetermined Significance
Rifaximin Versus No Intervention in Patients With IgA Monoclonal Gammopathy of Undetermined Significance
Fred Hutchinson Cancer Center
50 participants
Jan 22, 2026
INTERVENTIONAL
Conditions
Summary
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgA MGUS.
Eligibility
Inclusion Criteria7
- Age ≥ 18 years
- Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants
- Clinical diagnosis of IgA monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014)
- Agree to use adequate contraception
- For women of child-bearing potential: prior to study entry and for the duration of study participation
- For men: prior to study entry, for the duration of study participation, and one month after completion of rifaximin administration (for men)
- No antibiotic use in the preceding 2 weeks
Exclusion Criteria3
- Participants who are receiving other investigational agents
- Pregnant women
- Known hypersensitivity to rifaximin
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Given PO
Undergo blood sample collection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07209371